Respana Therapeutics, Inc.
Respana Therapeutics develops a monoclonal antibody therapeutic candidate intended to modulate dysregulated immune responses after infection, with a focus on post-infectious pulmonary complications. The program includes target identification, preclinical in vivo validation showing improved survival and no observed toxicity in animal models, and secured academic licensing and federal R&D funding to advance toward human testing.
Industries
N/A
Nr. of Employees
small (1-50)
Products
RT-002 (monoclonal antibody candidate)
A therapeutic monoclonal antibody candidate targeting a receptor involved in prolonged inflammatory responses after infection; developed to resolve inflammation and reduce downstream complications in preclinical models.
RT-002 (monoclonal antibody candidate)
A therapeutic monoclonal antibody candidate targeting a receptor involved in prolonged inflammatory responses after infection; developed to resolve inflammation and reduce downstream complications in preclinical models.
Services
Free consultation scheduling with a member of the clinical team to discuss suitability and next steps.
Free consultation scheduling with a member of the clinical team to discuss suitability and next steps.
Expertise Areas
- Antibody therapeutics development
- Pulmonary immunology and translational research
- Preclinical animal models and in vivo validation
- Bioprocess and recombinant protein manufacturing
Key Technologies
- Monoclonal antibodies
- Receptor-targeted immunomodulation
- In vivo animal models for pulmonary disease
- Recombinant protein expression and purification
News & Updates
Received three STTR awards from NIH NIAID (Phase I and Phase II) totaling over $3 million to support development.
First prize at the 3 Rivers Venture Fair Technology Showcase 2024.
Seed grants awarded from Phase 1 Ventures and Commonwealth of Pennsylvania.
Named runner-up for a MilliporeSigma Advance Biotech grant.
Received three STTR awards from NIH NIAID (Phase I and Phase II) totaling over $3 million to support development.
First prize at the 3 Rivers Venture Fair Technology Showcase 2024.
Seed grants awarded from Phase 1 Ventures and Commonwealth of Pennsylvania.
Named runner-up for a MilliporeSigma Advance Biotech grant.